STOCK TITAN

Xencor - XNCR STOCK NEWS

Welcome to our dedicated page for Xencor news (Ticker: XNCR), a resource for investors and traders seeking the latest updates and insights on Xencor stock.

Overview

Xencor Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of engineered antibody therapeutics. With a strong emphasis on protein engineering and innovative antibody therapeutics, Xencor focuses on improving treatment options for patients suffering from cancer and autoimmune diseases through its proprietary XmAb technology platform.

Proprietary XmAb Technology Platform

Xencor’s XmAb platform represents a significant advancement in antibody engineering. The technology allows for the augmentation of natural antibody immune functions while preserving a high degree of identity to naturally occurring antibodies. This precise and strategic modification results in antibodies with enhanced potency, improved safety profiles, and extended half-lives. The dual emphasis on maintaining the beneficial aspects of natural antibody structures along with the integration of novel functionalities enables the company to develop biotherapeutic candidates that are differentiated and potentially capable of breakthrough performance.

Pipeline and Collaborations

The company has established a robust pipeline consisting of multiple product candidates, many of which are advanced into clinical evaluations. Xencor’s approach is underpinned by a diversified business model that includes revenue generation from collaboration agreements, product licensing, and technology licensing. This multi-faceted strategy not only facilitates rapid clinical development but also leverages partnerships with global pharmaceutical entities to expand the reach and applicability of its engineered therapeutics.

Business Model and Market Position

Operating in the highly specialized realm of biotherapeutics, Xencor positions itself as an innovator in the field of antibody engineering. Its focus on designing antibodies that target new biological mechanisms allows it to meet unmet medical needs with improved therapeutic profiles. The company’s revenue model is strongly based on collaboration and licensing, which supports both internal development and industry-wide integration. By aligning cutting-edge research with strategic partnerships, Xencor demonstrates a commitment to enhancing patient outcomes and significantly contributing to the biopharmaceutical landscape.

Technological and Clinical Significance

The XmAb platform is central to Xencor’s technological prowess. The ability to finely tune antibody functions offers a scalable and adaptable solution to address various indications, such as autoimmune disorders and cancer. In doing so, Xencor not only advances clinical practice but also lays the foundation for future innovations in the field of biologics discovery. The company’s clear focus on harnessing innovative protein engineering techniques underscores its depth of expertise and solidifies its position as an important participant in the biotherapeutic market.

Key Differentiators

  • Innovative Platform: The XmAb technology provides a unique blend of increasing biological activity while retaining the safety benefits of natural antibodies.
  • Diversified Business Model: Revenue streams from collaborations, technology licensing, and product licensing enhance the company’s resilience and market adaptability.
  • Strategic Collaborations: Partnerships with pharmaceutical leaders amplify the reach and clinical potential of Xencor’s product candidates.
  • Clinical-Stage Focus: A robust clinical pipeline demonstrates the company's commitment to translating innovative research into tangible treatment options.

Conclusion

In summary, Xencor Inc stands out in the biopharmaceutical realm through its commitment to developing advanced engineered antibody therapeutics. The proprietary XmAb platform not only highlights its expertise in protein engineering but also reinforces its strategic position within a competitive industry. By integrating deep technological insight with a collaborative business model, Xencor continues to build a diversified portfolio that aims to address some of the most pressing medical challenges.

Rhea-AI Summary

Xencor, a clinical-stage biopharmaceutical company focused on engineered monoclonal antibodies and cytokines for treating cancer and autoimmune diseases, has announced its participation in several investor events.

  • Bernstein CD28 Day: Presentation on August 9 at 1:00 p.m. ET.
  • Wedbush PacGrow Healthcare Conference: Panel on August 10 at 1:10 p.m. ET.
  • BTIG Virtual Biotechnology Conference: Presentation on August 10 at 3:30 p.m. ET.
  • Canaccord Genuity Conference: Presentation on August 11 at 4:30 p.m. ET.
  • Piper Sandler West Coast Bus Tour: Presentation on August 12 at 4:00 p.m. ET.

A webcast of the Canaccord presentation will be available on Xencor's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.59%
Tags
conferences
-
Rhea-AI Summary

Xencor, Inc. (NASDAQ: XNCR) will release its second quarter 2021 financial results post-market on August 4, 2021. A conference call is scheduled for 4:30 p.m. ET to discuss these results and provide a corporate update. The live call can be accessed via phone or a webcast on the company's website. Xencor is a clinical-stage biopharmaceutical firm focusing on engineered monoclonal antibodies and cytokines targeting cancer and autoimmune diseases, with 22 candidates in clinical development leveraging its XmAb® technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
conferences earnings
-
Rhea-AI Summary

Xencor, Inc. (NASDAQ: XNCR) announced that Dr. Bassil Dahiyat, president and CEO, will present a corporate overview at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 1:00 p.m. ET. The presentation will cover Xencor's focus on developing engineered monoclonal antibodies and cytokines for cancer and autoimmune diseases. A webcast of the event will be available on the company's website, with a replay accessible for at least 30 days following the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
conferences
Rhea-AI Summary

Xencor, Inc. (NASDAQ: XNCR) announced that the FDA has granted emergency use authorization for sotrovimab, an engineered monoclonal antibody developed with Vir Biotechnology and GlaxoSmithKline to treat mild-to-moderate COVID-19 in high-risk patients. While not approved, sotrovimab shows an 85% reduction in hospitalization or death based on Phase 3 trial data. Xencor has licensed its Xtend technology to Vir to enhance antibody performance. The EUA will last as long as the COVID-19 emergency declaration is in effect.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
covid-19
-
Rhea-AI Summary

Xencor, a clinical-stage biopharmaceutical company (NASDAQ:XNCR), entered a licensing agreement with Bristol-Myers Squibb (NYSE:BMY) for its Xtend™ Fc technology to extend the half-life of the SARS-CoV-2 mAb Duo, designed for COVID-19 treatment. This antibody combination, discovered at Rockefeller University, is currently in Phase 1 clinical evaluation. Xencor, eligible for royalties from sales, emphasizes that its technology improves therapeutic performance, potentially lowering costs for antiviral therapies. The partnership aims to address urgent medical needs, particularly in the pandemic context.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
covid-19
-
Rhea-AI Summary

Xencor, a clinical-stage biopharmaceutical company focusing on engineered monoclonal antibodies and cytokines for cancer and autoimmune diseases, announced that its CEO, Bassil Dahiyat, will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Virtual Conference. The event is set for May 19, 2021, at 1:20 p.m. ET. Investors can access a live webcast on the company's website, with a replay available for 30 days afterward. Xencor has 21 clinical candidates utilizing its XmAb technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
conferences
Rhea-AI Summary

Xencor, a clinical-stage biopharmaceutical company, reported Q1 2021 financial results, achieving a total revenue of $34 million, an increase from $32.4 million in Q1 2020. The net loss narrowed to $2.5 million or $(0.04) per share, compared to a loss of $8.1 million the previous year. Cash and equivalents amounted to $577.1 million. Recently, Xencor initiated a Phase 1 study for XmAb564 and presented preclinical data at the AACR meeting. Future clinical studies are planned for XmAb717 and Tidutamab.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
-
Rhea-AI Summary

Xencor, Inc. (NASDAQ: XNCR) has initiated a Phase 1 clinical study for XmAb564, targeting autoimmune diseases. The first subject has been dosed in this randomized, double-blind, placebo-controlled trial, which evaluates the safety and tolerability of XmAb564 in healthy volunteers. XmAb564 is designed to selectively activate regulatory T cells while minimizing activation of other immune cells, aimed at improving therapeutic outcomes. Preliminary studies indicate it has favorable pharmacologic properties and promotes sustained Treg proliferation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
-
Rhea-AI Summary

Xencor, Inc. (NASDAQ: XNCR) announced its plans to release first quarter 2021 financial results after market close on May 5, 2021. A conference call will be held the same day at 4:30 p.m. ET to discuss the results and provide a corporate update. Interested parties can access the call by dialing (877) 359-9508 or through an online webcast available on Xencor's website. The company is focused on developing engineered monoclonal antibodies and cytokines for cancer and autoimmune disease treatments, with 21 candidates in clinical development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
conferences earnings
Rhea-AI Summary

Xencor, Inc. (NASDAQ:XNCR) announced new data presentation from its preclinical bispecific antibody and IL-12-Fc cytokine programs at the AACR Annual Meeting. The data showcases the potential of CD28 and XmAb 2+1 platforms, emphasizing their engineered cytokines' enhanced therapeutic indices. Notably, Xencor plans to submit an IND for their XmAb819 bispecific antibody in 2021 and start a Phase 1 study in early 2022. The IL-12-Fc fusions showed significant anti-tumor activity in preclinical models, indicating a promising future for Xencor's innovations in cancer therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Xencor (XNCR)?

The current stock price of Xencor (XNCR) is $9.69 as of April 1, 2025.

What is the market cap of Xencor (XNCR)?

The market cap of Xencor (XNCR) is approximately 682.8M.

What does Xencor Inc specialize in?

Xencor Inc specializes in the discovery and development of engineered antibody therapeutics, focusing on treatments for cancer and autoimmune diseases using its proprietary XmAb technology.

How does the XmAb technology platform work?

The XmAb platform utilizes advanced protein engineering to enhance natural antibody functions, resulting in antibodies that are both potent and safe while maintaining a structure similar to natural antibodies.

What is the primary revenue model for Xencor?

Xencor generates revenue primarily through collaboration agreements, product licensing, and technology licensing, partnering with major pharmaceutical companies to advance its biotherapeutic products.

How does Xencor differentiate itself in the biopharmaceutical industry?

Xencor differentiates itself through its proprietary XmAb technology, which combines novel immune functions with the inherent safety of natural antibodies, and a diversified business model that emphasizes strategic collaborations.

What therapeutic areas is Xencor focused on?

The company is primarily focused on developing treatments for cancer and autoimmune diseases by creating next-generation antibody therapeutics.

How does Xencor's business model support its clinical development?

By leveraging diverse revenue streams from collaborations and licensing agreements, Xencor is able to invest in advancing its robust pipeline, which includes several clinical-stage product candidates.

What role do strategic partnerships play at Xencor?

Strategic partnerships are integral to Xencor's operations, enabling the company to expand the clinical evaluation of its candidates and enhance its product development capabilities through collaborative efforts with other industry leaders.

How does Xencor contribute to advances in antibody therapeutics?

Xencor contributes through its innovative approach to antibody engineering, using the XmAb platform to develop therapeutics with improved safety, potency, and longevity, addressing critical treatment needs in complex diseases.
Xencor

Nasdaq:XNCR

XNCR Rankings

XNCR Stock Data

682.78M
69.66M
1.13%
107.68%
7.96%
Biotechnology
Pharmaceutical Preparations
Link
United States
PASADENA